Viridian Therapeutics Statistics
NASDAQ: VRDNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
18.66+0.32 (+1.74%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Viridian Therapeutics by the numbers
Viridian Therapeutics has a market capitalization of $2.11 billion based on 113.29M shares outstanding. With trailing EPS of $-3.45, Viridian Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 14.7% below its 50-day average and 17.3% below its 200-day average.
Average daily trading volume is 1.71M shares, or about $32.0 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
VRDN valuation vs. peer median
| Metric | VRDN | Peer median | Difference |
|---|---|---|---|
| Market cap | $2.11B | $2.07B | +2% |
| Avg. volume | 1.71M | 1.01M | +70% |
Peer median across 8 companies: PRGO, MLYS, SDGR, VERA, PVLA, PHVS, LKFT, AUPH.
Valuation
- Market cap
- $2.11B
- Price / sales (latest FY)
- 29.84
- EPS (TTM)
- $-3.45
- Shares outstanding
- 113.29M
Price and trading
- Previous close
- 18.34
- Open
- 18.31
- Day range
- 18.16 – 18.71
- 52-week range
- 13.18 – 34.29
- 52-week change
- -14.44%
- Beta
- —
- Volume
- 1.33M
- Average volume
- 1.71M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 4, 2026
Additional statistics
- Market Cap
- 2.11B
- Forward Pe
- -6.81
- Eps
- -3.45
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 34.29
- Week52 Low
- 13.18
- Avg Volume
- 1.71M
- Shares Outstanding
- 113.29M
- Ma50
- 21.87
- Ma200
- 22.56
- Earnings Date
- Nov 4, 2026
- Pct From52w High
- -45.58%
- Pct From52w Low
- 41.58%